Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Aroa Soriano Fernández

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Aroa Soriano Fernández

Aroa Soriano Fernández

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Marta Garrido Pontnou, Miguel Segura Ginard, Lorena Valero Arrese, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Gabriela Guillén Burrieza, Josep Roma Castanyer, Andrea Vilaplana Blanes, Sergio Manresa Vera, Margarita Ortega Blanco, María Rosario Pérez- Torres Lobato, Asbleidy Carolina Torres Barbosa
Funding agency: Instituto de Salud Carlos III
Funding: 369260
Reference: PMP21/00073
Duration: 01/01/2022 - 31/12/2025

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Lorena Valero Arrese, Sergio Manresa Vera, Mariona Morell Daniel
Funding agency: Instituto de Salud Carlos III
Funding: 214170
Reference: PI21/01661
Duration: 01/01/2022 - 31/12/2024

Quatsomes as a novel nanomaterial platform for nucleic acids delivery

IP: Miguel Segura Ginard
Collaborators: Aroa Soriano Fernández, Quatsomes as a novel nanomaterial platform for nucleic acids delivery, Lucas Moreno Martín-Retortillo
Funding agency: Instituto de Salud Carlos III
Funding: 83600
Reference: DTS20/00018
Duration: 01/01/2021 - 31/12/2022

JARC: Joint Action on Rare Cancers Grant Agreement: 724161 VHIR involved in WP9 Task 2 : Objective Use of relevant paediatric preclinical models (patients derived xenografts, genetically modified models, other preclinical model) for experimental

IP: Miguel Segura Ginard
Collaborators: Aroa Soriano Fernández, Josep Roma Castanyer
Funding agency: Ex. Agency for Health Consumers (EAHC)-CHAFEA
Funding: 6959.28
Reference: JARC_3HP-CHAFEA2015
Duration: 01/10/2016 - 30/09/2019

Related news

Dra. Begoña Benito i Dr. Josep Samitier

We promote synergies between VHIR and IBEC with a collaboration day

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

Cribratge-anemia-falciforme

Neonatal detection of sickle cell disease in Catalonia reduces complications

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Infermera d'assaigs clínics amb pacient

The voice of patients as a driving force in clinical trials

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

See more

Related professionals

Anna Sanjuan Viaplana

Anna Sanjuan Viaplana

Medium Grade Technician
Statistics and Bioinformatics Unit (UEB)
Preclinical Core Facilities
External Strategy Directorate
Read more
Garcia Blanco, Alejandra

Garcia Blanco, Alejandra

Research technician
Neurodegenerative Diseases
Read more
Joan Compte Barrón

Joan Compte Barrón

Predoctoral researcher
Neurodegenerative Diseases
Read more
Piqué Ponti, Julia

Piqué Ponti, Julia

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.